Market Place
Sourcing Support
Atea rejects `undervalued` offer from Concentra
31 May 2023 //
FIERCE BIOTECH
Atea confirms unsolicited cash proposal from Tang Capital’s Concentra
23 May 2023 //
ENDPTS
Concentra rebounds with a shot at COVID-19-focused Atea
22 May 2023 //
FIERCE BIOTECH
Jounce Therapeutics Announces Closing of Tender Offer
03 May 2023 //
GLOBENEWSWIRE
Termination of Proposed Business Combination of Jounce and Redx Pharma plc
03 Apr 2023 //
GLOBENEWSWIRE
Jounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobs
28 Mar 2023 //
HEALTH ET
Jounce Enters Into Agreement to Be Acquired by Concentra Biosciences
27 Mar 2023 //
GLOBENEWSWIRE
Jounce Announces Results from Data Review of INNATE Phase 2 Trial of JTX-8064
16 Mar 2023 //
GLOBENEWSWIRE
Biotech makes surprise bid to snatch Jounce out of Redx’s hands
15 Mar 2023 //
FIERCE BIOTECH
Jounce Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
14 Mar 2023 //
GLOBENEWSWIRE
Biotech firms Redx Pharma and Jounce Therapeutics to merge in $425 million deal
24 Feb 2023 //
REUTERS
Redx and Jounce Announce Recommended Business Combination
23 Feb 2023 //
GLOBENEWSWIRE
Jounce Therapeutics Announces Restructuring
22 Feb 2023 //
GLOBENEWSWIRE
Gilead buys out rights to cancer therapy from Jounce for $67 million
28 Dec 2022 //
PRESS RELEASE
Jounce Therapeutics Presents INNATE Ph1 and SELECT Clinical Trial dat
08 Dec 2022 //
GLOBENEWSWIRE
Jounce Therapeutics Reports Third Quarter 2022 Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Jounce earns clinical milestone payment under the CCR8 agreement Gilead
02 Nov 2022 //
PRESS RELEASE
Jounce Therapeutics to Announce Third Quarter 2022 Financial Results
27 Oct 2022 //
GLOBENEWSWIRE
Jounce Therapeutics to Present Multiple Posters at the SITC 37th Annual Meeting
20 Oct 2022 //
GLOBENEWSWIRE
Jounce’s latest setback dampens outlook for another cancer immunotherapy target
31 Aug 2022 //
BIOPHARMADIVE
2 yrs after PhII setback, Jounce`s lead I/O drug flops again
30 Aug 2022 //
ENDPTS
Jounce Therapeutics to Announce Second Quarter 2022 Financial Results
28 Jul 2022 //
GLOBENEWSWIRE
Jounce Therapeutics to Present at Upcoming Investor Conferences
17 May 2022 //
GLOBENEWSWIRE
Jounce Therapeutics Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Jounce Therapeutics to Announce First Quarter 2022 Financial Results
28 Apr 2022 //
GLOBENEWSWIRE
Jounce Therapeutics to Participate in Raymond James LILRB/ILT Symposium
20 Apr 2022 //
GLOBENEWSWIRE
Jounce Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
02 Mar 2022 //
GLOBENEWSWIRE
Jounce Tx to Participate in Cowen & Co. 42nd Annual Health Care Conference
28 Feb 2022 //
GLOBENEWSWIRE
Jounce Tx to Announce Q4 and Full Year 2021 Financial Results on March 2
23 Feb 2022 //
GLOBENEWSWIRE
Jounce Therapeutics to Present at Upcoming Investor Conferences in January
04 Jan 2022 //
GLOBENEWSWIRE
Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
15 Sep 2021 //
GLOBENEWSWIRE
Jounce Therapeutics Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
Jounce Second Quarter 2021 Financial Results and Host a Conference Call
29 Jul 2021 //
GLOBENEWSWIRE
Jounce Therapeutics to Participate in William Blair’s Biotech Focus Conference
07 Jul 2021 //
GLOBENEWSWIRE
Jounce Provides Update on INNATE Study and Discovery Pipeline Expansion
23 Jun 2021 //
GLOBENEWSWIRE
Jounce Therapeutics to Host Virtual R&D Day on June 23, 2021
16 Jun 2021 //
GLOBENEWSWIRE
Jounce Therapeutics` Exclusive License Agreement with Gilead Sciences
15 Jun 2021 //
GLOBENEWSWIRE
Jounce Therapeutics Reports First Quarter 2021 Financial Results
04 May 2021 //
GLOBENEWSWIRE
Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE
28 Apr 2021 //
GLOBENEWSWIRE
Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at (AACR)
10 Mar 2021 //
JOUNCETX
Jounce Therapeutics Announces Pricing of $56.25
09 Mar 2021 //
GLOBENEWSWIRE
Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064
13 Jan 2021 //
GLOBENEWSWIRE
Jounce Therapeutics Added to NASDAQ Biotechnology Index
16 Dec 2020 //
GLOBENEWSWIRE
Jounce Therapeutics Receives Study May Proceed Letter from US FDA JTX-8064
16 Nov 2020 //
GLOBENEWSWIRE
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program
11 Nov 2020 //
GLOBENEWSWIRE
Jounce shares take a beating as their lead drug spurs only in PhII
03 Nov 2020 //
ENDPTS
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement
01 Sep 2020 //
GLOBENEWSWIRE
Gilead deal reignites optimism in a cancer biotech
01 Sep 2020 //
BIOPHARMADIVE
Jounce Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811
22 Jun 2020 //
PRESS RELEASE
Jounce to Present First Preclinical Data on Anti-CCR8 Antibody JTX-1811
15 May 2020 //
GLOBENEWSWIRE
Jounce Therapeutics Presents New Vopratelimab Predictive Biomarker
06 Feb 2020 //
PRESS RELEASE
